Kiromic BioPharma, a preclinical biotech developing immunotherapies for blood cancers and solid tumors, raised $15 million by offering 1.3 million shares at $12, the low end of the range of $12 to $14.
Kiromic BioPharma plans to list on the Nasdaq under the symbol KRBP. ThinkEquity acted as sole bookrunner on the deal.
